The aim of this study is to lay the bases for an ambitious project that reports and records all the epidemiological-clinical information of the cases of endometrial carcinoma diagnosed and treated in the reference oncology centers involved on the national territory, to create a process of analysis of the data
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* diagnosis of endometrial cancer (stage I-IV, G1-3, and special histotypes)
* age \> 18 years
* American Society of Anesthesiologists classification (ASA score) 1-3
* patients undergoing staging, cytoreduction or diagnostic surgery with acquisition of histological examination on which IHC and/or NGS studies have been performed for the molecular profile of the carcinoma
* Signed informed consent
Exclusion Criteria:
* patients with missing information
* patients not treated in the participating centers for which only partial and fragmented information will be available
* molecular profile not known and\\or not recoverable and retrospectively analysable
Primary outcome measure(s)
Disease Free Survival — Baseline. To evaluate the impact of the immuno-molecular and clinical profile of endometrial cancer on the outcomes of DFS (Disease-Free Survival).
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.